Results 231 to 240 of about 213,774 (293)

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

Molecular guided therapy leading to exceptional response in relapsed osteosarcoma. [PDF]

open access: yesFront Pharmacol
Wert E   +8 more
europepmc   +1 more source

Case Report of Maxillary Alveolar Rhabdomyosarcoma Misdiagnosed as Periapical Lesion: Clinicopathological Alerts and Life‐Saving Lessons for Dentists

open access: yesAustralian Endodontic Journal, EarlyView.
ABSTRACT This report describes a rare case of alveolar rhabdomyosarcoma initially presenting with clinical features resembling an endodontic lesion. A 15‐year‐old male presented with progressive right maxillary swelling initially treated as a dental abscess.
Saliha Akçay Köprücü   +3 more
wiley   +1 more source

Effect of Intracanal Medications on the Viability of Human Periodontal Ligament‐Derived Mesenchymal Stem Cells

open access: yesAustralian Endodontic Journal, EarlyView.
ABSTRACT This in vitro study evaluated the effects of intracanal medications on the metabolic activity and adhesion of human periodontal ligament‐derived mesenchymal stem cells. Tested groups included Control (without medication), Triple Antibiotic Paste (TAP), Double Antibiotic Paste (DAP), calcium hydroxide with saline, calcium hydroxide with 2 ...
Arian Braido   +7 more
wiley   +1 more source

Histological prognostic factors in canine appendicular osteosarcoma: 57 cases (2014-2022). [PDF]

open access: yesSci Rep
Miyagi H   +6 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

AVIL promotes osteosarcoma progression and cisplatin resistance via ARP2/3-mediated DNA damage repair. [PDF]

open access: yesTransl Oncol
Chen Z   +9 more
europepmc   +1 more source

Overexpression of Transferrin Receptor in Esophageal Squamous Cell Cancer Suggests Poor Prognosis and Potential Therapy

open access: yesCancer Science, EarlyView.
This study aimed to evaluate transferrin receptor (TfR) expression in human esophageal squamous cell cancer (ESCC) specimens and investigate the correlation between TfR overexpression and clinicopathological characteristics. Furthermore, we explored the potential of targeting iron metabolism pathways as a novel therapeutic strategy for ESCC.
Naoki Ikenaga   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy